Navigation Links
BioCryst to Present at JMP Securities Healthcare Conference
Date:10/2/2009

BIRMINGHAM, Ala., Oct. 2 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Jon P. Stonehouse, President and Chief Executive Officer of BioCryst and Stuart Grant, Chief Financial Officer of BioCryst, plan to provide a corporate summary at the JMP Securities Healthcare Focus Conference in New York on Tuesday, October 6, 2009 at 3:30 p.m. Eastern Time.

Links to a live audio Web cast and replay of the presentation may be accessed on the BioCryst Web site at www.biocryst.com.

About BioCryst

BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer and inflammatory diseases. BioCryst has progressed two novel compounds into late-stage pivotal clinical trials; peramivir, an anti-viral for influenza, and forodesine, a purine nucleoside phosphorylase (PNP) inhibitor for cutaneous T-cell lymphoma (CTCL). Utilizing crystallography and structure-based drug design, BioCryst continues to discover additional compounds and to progress others through pre-clinical and early development to address the unmet medical needs of patients and physicians. The Company's strategic alliances with the U.S. Department of Health and Human Services, Shionogi & Co., Ltd., Green Cross Corporation and Mundipharma International Holdings Limited validate its scientific foundation and the utility of its product candidates. For more information, please visit the Company's Web site at www.biocryst.com.

This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cau
'/>"/>

SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. BioCryst Initiates Enrollment in Pivotal Trial of Forodesine HCL in Patients with Cutaneous T-Cell Lymphoma (CTCL)
2. BioCryst Provides Forodesine HCl Update
3. BioCryst Updates Peramivir Clinical Development Plan
4. BioCryst Announces Initiation of Phase II Study of Intramuscular Peramivir for the Treatment of Seasonal Influenza
5. BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting
6. BioCryst Pharmaceuticals to Announce Peramivir Update and First Quarter 2009 Financial Results on May 8, 2009
7. BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results
8. BioCryst Pharmaceuticals Reports Positive Results of Shionogi & Co. Sponsored Phase 3 Studies of i.v. Peramivir for Influenza
9. BioCryst Provides Update Regarding Peramivir for Influenza
10. BioCryst Clarifies Government Declaration Regarding Peramivir
11. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)...  Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR ) today ... company at the following conferences. , Deutsche Bank ... May 29, 2013 , Presentation time: 12:00 p.m. P.T. ... , Presentation date: Wednesday June 5, 2013 , Presentation ... A live webcast and 30-day archive of these presentations will ...
(Date:5/22/2013)...  Grifols, a global healthcare company based in ... study demonstrating that a higher dose of PROLASTIN © ... the alpha 1 protein in patients with alpha ... within the normal range for healthy individuals. AAT deficiency ... of the alpha 1 proteinase inhibitor (A1PI) protein ...
(Date:5/22/2013)... LAKE CITY , May 22, 2013 /PRNewswire/ ... ) today announced it received 510(k) clearance from ... Varian,s diagnostic X-ray image processing workstation that combines ... on one platform.  Varian,s Nexus DRF Digital X-Ray ... a variety of image receptors, including CCD cameras ...
Breaking Medicine Technology:Avanir Pharmaceuticals to Participate in Two Upcoming Investor Conferences 2Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 2Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 3Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 4Varian Medical Systems Receives FDA 510(k) Clearance of its Nexus DRF Digital X-Ray Imaging System 2
... designed for more uniform drug ... ... Boston,Scientific Corporation (NYSE: BSX ) today announced comprehensive data ... historically controlled trials, which evaluate,the TAXUS(R) Liberte(R) Paclitaxel-Eluting Stent System in ...
... with Kogenate FS Reduces the,Risk of Joint Damage ... Damage, BERKELEY, Calif., Oct. 10 Bayer ... Drug Administration (FDA) has,approved routine prophylaxis with Kogenate(R) ... bleeding episodes and the risk of,joint damage in ...
Cached Medicine Technology:Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent 2Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent 3Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent 4Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent 5Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent 6FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 2FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 3FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 4FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 5
(Date:5/22/2013)... 22, 2013 Mari’s Skin Care, a peaceful ... the first in the state of Texas to offer a ... Medical and Esthetic Tissue Activation, also known as collagen ... years in Europe, but has just recently made its way ... skin from inside out by building collagen and elastin. ...
(Date:5/22/2013)... (PRWEB) May 22, 2013 The ... (Amino Resins, Melamine Formaldehyde, Melamine Urea Formaldehyde), Applications ... - Global Trends and Forecasts to 2018" defines ... forecasting of the global volume and revenue. ... for the Global Amino Resins Market with analysis ...
(Date:5/21/2013)... May 22, 2013 Spring is the ... nutrition--from farmers' markets filled with whole foods to weather ... most of the season the nutrition experts at Brilliant ... not to miss. , 1. Eating Locally, With the ... shoppers to linger and explore, spring is a great ...
(Date:5/21/2013)... May 21, 2013 Heritage Woods of ... BMA affordable assisted living community, is hosting a Quality Home ... at 2 p.m. on Tuesday, May 28. , The community, ... serves older adults of all incomes, including those on Medicaid, ... Arthritis program is open to the public. There is ...
(Date:5/21/2013)... Standard advice for mattress shoppers often consists ... given industry’s less than exceptional satisfaction ratings and the ... Consumer Mattress Reports sets out to revise this advice ... .” , This article addresses several components of the ... not be readily apparent to many shoppers. From prices ...
Breaking Medicine News(10 mins):Health News:Mari's to Offer New Treatment from Europe 2Health News:Asia-Pacific Leads in Consumption of Urea Formaldehyde Resins Followed by Europe and North America - New Report by MarketsandMarkets 2Health News:Asia-Pacific Leads in Consumption of Urea Formaldehyde Resins Followed by Europe and North America - New Report by MarketsandMarkets 3Health News:Brilliant Nutrition Offers 5 Ways to Live Healthier and Inspired this Spring 2Health News:Brilliant Nutrition Offers 5 Ways to Live Healthier and Inspired this Spring 3Health News:Heritage Woods of Dwight Affordable Assisted Living to Host Informational Program on the Do's and Don'ts of Arthritis 2Health News:Choosing the Best Mattress Simplified in Consumer Mattress Reports’ Latest Article 2
... News) -- Adding more weight to concerns about possible ... people who take the drugs, known as bisphosphonates, may be ... (femur). Osteoporosis is a bone-thinning disease that is ... unusual type of break that often occurs spontaneously, without any ...
... team of researchers, including a scientist from the Viral ... a type of herpesvirus infection of the eye is ... that causes blindness in the elderly. The scientists ... the production of vascular endothelial growth factor, or VEGF, ...
... 2012) Behavioral support from peers and primary care office ... as much as starting a new drug, a new study ... Medicine San Antonio, is the senior author. The randomized, ... support from peers and primary care office staff could ...
... (HealthDay News) -- Men with severe gum disease, known as ... new study that finds young men and the elderly at ... a large study to identify almost 33,000 men with ... condition. Of these study participants, about 12 percent ...
... quality of care you receive be affected by how your ... at Brigham and Women,s Hospital (BWH), doctors who dictated their ... who used structured documentation. The study is published ... Association . The researchers evaluated 18,569 visits by 7,000 ...
... Spanish . Flexible sigmoidoscopy, a screening ... fewer side effects than colonoscopy, is effective in reducing the ... according to research sponsored by the National Cancer Institute, part ... that spanned almost 20 years, researchers found that overall colorectal ...
Cached Medicine News:Health News:More Research Points to Long-Term Ills With Bone Drugs 2Health News:Type of viral infection of eye associated with disease causing blindness in the elderly 2Health News:Behavioral support from peers, staff lowers patients' blood pressure 2Health News:Behavioral support from peers, staff lowers patients' blood pressure 3Health News:Severe Gum Disease, Impotence May Be Linked 2Health News:To dictate or not to dictate? 2Health News:NIH study finds sigmoidoscopy reduces colorectal cancer rates 2Health News:NIH study finds sigmoidoscopy reduces colorectal cancer rates 3Health News:NIH study finds sigmoidoscopy reduces colorectal cancer rates 4
Stainless steel lancet blade in stainless steel....
Sharp diamond shaped double blade in stainless steel....
... CT MIYABI system is a ... CT scanner on rails (Sliding ... angiography unit. Both systems use ... which can be switched between ...
AXIOM Multistar is a ceiling-mounted single plane C-Arm system for universal angiography, diagnostics and intervention...
Medicine Products: